Significant FBXO10 overexpression was observed in multiple cancers compared with that in corresponding normal tissues, including bladder urothelial carcinoma (BLCA), breast invasive carcinoma (BRCA), cervical squamous cell carcinoma/endocervical adenocarcinoma (CESC), cholangiocarcinoma (CHOL), colon adenocarcinoma (COAD), esophageal carcinoma (ESCA), head–neck squamous cell carcinoma (HNSC), HCC (LIHC), lung adenocarcinoma (LUAD), lung squamous cell carcinoma (LUSC), rectal adenocarcinoma (READ), stomach adenocarcinoma (STAD), and uterine corpus endometrial carcinoma (UCEC). This evidence concerns the gene FBXO10 and uterine corpus endometrial carcinoma.